Literature DB >> 11982504

Increased phasic activity of dopaminergic neurones in the rat ventral tegmental area following pharmacologically elevated levels of endogenous kynurenic acid.

S Erhardt1, G Engberg.   

Abstract

Kynurenic acid (KYNA) is an antagonist of ionotropic glutamate receptors, preferentially blocking the glycine-site of the N-methyl-D-aspartate (NMDA) receptor. In the present electrophysiological study, the firing pattern of dopamine (DA) neurones of rat ventral tegmental area (VTA) was investigated following pharmacologically elevated endogenous levels of KYNA by means of an inhibitor of kynurenine 3-hydroxylase (PNU 156561A). Pre-treatment with PNU 156561A (40 mg kg-1, i.v., 5-9 h) caused a threefold increase in endogenous KYNA in whole brain levels and also evoked a significant increase in firing rate and bursting activity of VTA DA neurones. Administration of D-cycloserine (2-128 mg kg-1, i.v.), a partial agonist at the glycine-site of the NMDA-receptor, was found to reverse the increase in firing rate and bursting activity as induced by elevated concentrations of KYNA. The electrophysiological effects of elevated KYNA levels were in all essential mimicked by administration of the NMDA-receptor antagonist MK 801 (0.05-1.6 mg kg-1, i.v.). Thus, the effects of elevated endogenous brain KYNA observed in the present study are likely to be carried out by NMDA receptor antagonism. In conclusion, this study shows that an increase in endogenous KYNA levels produces significant actions on the tonic afferent control of the firing pattern of VTA DA neurones. Given the psychotomimetic effects of NMDA-receptor antagonists, e.g. phencyclidine and ketamine, the state of hyperactivity of mesocorticolimbic DA system induced by elevated levels of KYNA may represent a pathophysiological condition analogous to that seen in schizophrenic patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11982504     DOI: 10.1046/j.1365-201X.2002.00962.x

Source DB:  PubMed          Journal:  Acta Physiol Scand        ISSN: 0001-6772


  28 in total

1.  Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia.

Authors:  Klas R Linderholm; Elisabeth Skogh; Sara K Olsson; Marja-Liisa Dahl; Maria Holtze; Göran Engberg; Martin Samuelsson; Sophie Erhardt
Journal:  Schizophr Bull       Date:  2010-08-20       Impact factor: 9.306

2.  Anterior thalamic lesions produce chronic and profuse transcriptional de-regulation in retrosplenial cortex: A model of retrosplenial hypoactivity and covert pathology.

Authors:  G L Poirier; K L Shires; D Sugden; E Amin; K L Thomas; D A Carter; J P Aggleton
Journal:  Thalamus Relat Syst       Date:  2008-03

3.  Inhibition of Large Neutral Amino Acid Transporters Suppresses Kynurenic Acid Production Via Inhibition of Kynurenine Uptake in Rodent Brain.

Authors:  Airi Sekine; Yusuke Kuroki; Tomomi Urata; Noriyuki Mori; Tsutomu Fukuwatari
Journal:  Neurochem Res       Date:  2016-05-09       Impact factor: 3.996

Review 4.  Kynurenic Acid in Schizophrenia: A Systematic Review and Meta-analysis.

Authors:  Eric Plitman; Yusuke Iwata; Fernando Caravaggio; Shinichiro Nakajima; Jun Ku Chung; Philip Gerretsen; Julia Kim; Hiroyoshi Takeuchi; M Mallar Chakravarty; Gary Remington; Ariel Graff-Guerrero
Journal:  Schizophr Bull       Date:  2017-07-01       Impact factor: 9.306

5.  Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes.

Authors:  Ikwunga Wonodi; O Colin Stine; Korrapati V Sathyasaikumar; Rosalinda C Roberts; Braxton D Mitchell; L Elliot Hong; Yasushi Kajii; Gunvant K Thaker; Robert Schwarcz
Journal:  Arch Gen Psychiatry       Date:  2011-07

Review 6.  Schizophrenia as an inflammation-mediated dysbalance of glutamatergic neurotransmission.

Authors:  N Muller; M Schwarz
Journal:  Neurotox Res       Date:  2006-10       Impact factor: 3.911

Review 7.  Glutamatergic synaptic dysregulation in schizophrenia: therapeutic implications.

Authors:  Joseph T Coyle; Alo Basu; Michael Benneyworth; Darrick Balu; Glenn Konopaske
Journal:  Handb Exp Pharmacol       Date:  2012

8.  Elevated levels of kynurenic acid in the cerebrospinal fluid of patients with bipolar disorder.

Authors:  Sara K Olsson; Martin Samuelsson; Peter Saetre; Leif Lindström; Erik G Jönsson; Conny Nordin; Göran Engberg; Sophie Erhardt; Mikael Landén
Journal:  J Psychiatry Neurosci       Date:  2010-05       Impact factor: 6.186

Review 9.  N-Methyl-D-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives.

Authors:  Mark J Millan
Journal:  Psychopharmacology (Berl)       Date:  2005-03-10       Impact factor: 4.530

Review 10.  Pharmacological manipulation of kynurenic acid: potential in the treatment of psychiatric disorders.

Authors:  Sophie Erhardt; Sara K Olsson; Göran Engberg
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.